Heidelberg and Inserm have scored exits after an acquisition that followed MYR's chronic hepatitis delta virus treatment receiving European regulatory approval.

MYR, a Germany-based chronic hepatitis therapy developer spun out of Heidelberg University and French state research institute Inserm, has agreed to an acquistion by pharmaceutical firm Gilead Sciences for nearly €1.2bn ($1.4bn) in cash. Gilead will pay the $1.4bn sum once the deal is completed, subject to customary conditions, and MYR could receive up to…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.